RAICHUR, Indien, 13. März 2025 /PRNewswire/ — Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), ein führender Hersteller von Wirkstoffen und Formulierungen, gibt bekannt, dass der Sachverständigenausschuss (SEC) der CDSCO sein neues Prüfpräparat (Investigational New Drug, IND) […]
Creating this hospital of the future in Philadelphia has been made possible in part by a gift from Aileen and Brian Roberts and their family—the largest single donation the hospital has received in its 170-year […]
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 […]
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at […]
YONGIN, South Korea, March 12, 2025 /PRNewswire/ — GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 […]
